COMMUNIQUÉS West-GlobeNewswire

CLS Holdings USA Provides an Update to the First Complete Year of Adult Use Cannabis in Nevada

12/07/2018 - 14:00

Total Sales and Tax Revenue Higher than Initial Forecasts LAS VEGAS, July 12, 2018 (GLOBE NEWSWIRE) -- CLS Holdings USA, Inc. (OTCQB:CLSH) “CLS,” a diversified cannabis company operating as Cannabis Life Sciences and a [...]

Sirona Biochem Announces CFDA Approval of SGLT2 Inhibitor for Phase I Clinical Trial

12/07/2018 - 14:00

VANCOUVER, British Columbia, July 12, 2018 (GLOBE NEWSWIRE) -- Sirona Biochem Corp . (TSX-V:SBM) (FSE:ZSB) (the “ Company ”) announced today that partner, Jiangsu Wanbang Biopharmaceuticals (“Wanbang”), has confirmed [...]

Cue Biopharma Produces Immuno-STAT™ Biologic Candidate for Treatment of Autoimmune Disease Under Collaboration and License Agreement with Merck

12/07/2018 - 14:00

CAMBRIDGE, Mass., July 12, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc., an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat [...]

HCi Viocare Rebrands Itself and Becomes Rafina Innovations Inc.

12/07/2018 - 13:44

Glasgow, Scotland, July 12, 2018 (GLOBE NEWSWIRE) -- HCi Viocare (OTCQB:VICA) , is pleased to announce that, further to our Current Report on Form 8-K filed June 15, 2018, HCi Viocare has completed a name change [...]

Managers' transactions

12/07/2018 - 13:36

Company Announcement No. 12/2018 12 July 2018 Attachment No 12 2018 US_Managers transactions

Zynerba Pharmaceuticals Announces New FAB-C Phase 2 Open-Label Data in Patients with Fragile X Syndrome

12/07/2018 - 13:30

- Significant Improvements in Behavioral Symptoms Observed in Patients and Sustained through 38 Weeks of Treatment with ZYN002 - - Presentation Today at the 16 th NFXF International Fragile X Conference - DEVON, Pa., [...]

Asterias Biotherapeutics Announces New Exclusive License Agreement with The Regents of the University of California for Stroke IP; Second Pre-Clinical Collaboration Initiated to Test the Efficacy of AST-OPC1 for the Treatment of Stroke

12/07/2018 - 13:00

AST-OPC1 has Demonstrated Positive Safety Profile and Promising Signs of Efficacy in a Phase 1/2a Trial for Severe Spinal Cord Injury FREMONT, Calif., July 12, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. ( [...]

Xenon Pharmaceuticals Announces At-The-Market Equity Offering

12/07/2018 - 13:00

BURNABY, British Columbia, July 12, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, announced today that it has entered into an at-the-market equity [...]

Allergy Therapeutics PLC: Trading Update

12/07/2018 - 13:00

Allergy Therapeutics plc (“Allergy Therapeutics” or the “Group”) Trading update Group’s market share continues to grow 12 July 2018 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology [...]

ProQR Announces Presentations on Programs in Ophthalmology at Conferences in July

12/07/2018 - 13:00

LEIDEN, the Netherlands, July 12, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe [...]

Microbix to Present at Okanagan Capital Conference

12/07/2018 - 13:00

Conference Introduces Growth Companies to Investors, July 12-14, 2018 TORONTO, July 12, 2018 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX:MBX) (Microbix®), an innovator of biological products and technologies, [...]

Unum Therapeutics to Present Pre-Clinical Data on its Antibody-Coupled T Cell Receptor (ACTR) Platform at the American Society of Hematology (ASH) Summit on Emerging Immunotherapies for Hematological Diseases

12/07/2018 - 13:00

CAMBRIDGE, Mass., July 12, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ:UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies based on its novel, universal [...]

InMode Introduces Triton: The World’s First and Only Simultaneous Multi-Wavelength Hair Removal

12/07/2018 - 13:00

NEW YORK, July 12, 2018 (GLOBE NEWSWIRE) -- InMode Ltd., a manufacturer and distributor of medical-aesthetic technology to doctors around the world, is pleased to announce the launch and FDA clearance of the Triton hair [...]

Zogenix Announces Positive Top-line Results from Second Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome

12/07/2018 - 13:00

Primary Endpoint Achieved - Statistically Significant Convulsive Seizure Reduction for ZX008 versus Placebo for Adjunctive Treatment of Seizures ZX008 Also Demonstrated Statistical Significance in All Key Secondary [...]

Auxly Announces Director Resignation

12/07/2018 - 13:00

VANCOUVER, British Columbia, July 12, 2018 (GLOBE NEWSWIRE) -- Auxly Cannabis Group Inc. (TSX.V:XLY) (" Auxly " or the " Company ") has announced today that following his appointment as Chief Executive Officer of a [...]

ViaDerma Provides an Update to Shareholders via a Letter from the CEO

12/07/2018 - 11:00

The Company is also in early stage discussions to sell its product on TV LOS ANGELES, July 12, 2018 (GLOBE NEWSWIRE) -- ViaDerma, Inc., (“Company”) (OTC Pink:VDRM), is pleased to announce it has posted a letter from [...]

Shire plc : Rule 2.9 Announcement

12/07/2018 - 08:00

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 12 July 2018 Shire [...]

Saniona receives milestone payment from Boehringer Ingelheim

12/07/2018 - 08:00

PRESS RELEASE July 12, 2018 Saniona, a leading biotech company within ion-channel research, today announced that Boehringer Ingelheim has selected the first candidate for pre-clinical and clinical development under [...]

Genmab Enters Strategic Partnership with Immatics to Discover and Develop Next Generation Bispecific Cancer Immunotherapies

12/07/2018 - 07:56

Company Announcement Genmab gains exclusive access to multiple novel proprietary tumor targets identified by Immatics Biotechnologies’ XPRESIDENT ® technology Creation of novel immuno-oncology drugs combining Genmab and [...]